DecisonDx Prelude – pro
DCISionRTpurports to identify patients with 3 distinct risk profiles:
Low Risk patients with a low recurrence risk with or without adjuvant RT.
Elevated Risk patients with significant benefit to recurrence risk with adjuvant RT.
Residual Risk patient with an excessive recurrence risk remaining after BCS+RT, potentially warranting intensified or alternative treatment approaches.
This test has not been prospectively studies, and validation comes form a single set of researchers.
L. Sun et al, Molecular Testing in Breast Cancer: Current Status and Future Directions. Volume 23, Issue 11, November 2021, Pages 1422-1432
Cancer Research 2018, Published Online 12/01/2018
Weinmann, S et al. Validation of a ductal carcinoma in situ biomarker profile for risk of recurrence after breast-conserving surgery with and without radiation therapy, Clinical Cancer Research 2020, Published Online 4/27/2020
Warnberg et al. Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma in Situ (DCIS) of the Breast in a Randomized Clinical Trial (SweDCIS). Cancers 2021.
Vicini,F et al. A Novel Biosignature Identifies Patients With DCIS With High Risk of Local Recurrence After Breast Conserving Surgery and Radiation Therapy. IJROBP 2022, Published Online 09/15/2022